A citation-based method for searching scientific literature

Bryce C Simes, Gordon G MacGregor. Diabetes Metab Syndr Obes 2019
Times Cited: 9







List of co-cited articles
15 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
44

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
33

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
33

Sulfonylureas and their use in clinical practice.
Daniele Sola, Luca Rossi, Gian Piero Carnevale Schianca, Pamela Maffioli, Marcello Bigliocca, Roberto Mella, Francesca Corlianò, Gian Paolo Fra, Ettore Bartoli, Giuseppe Derosa. Arch Med Sci 2015
126
33

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
274
22

Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Nancy A Thornberry, Baptist Gallwitz. Best Pract Res Clin Endocrinol Metab 2009
96
22


SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials.
Robert Puckrin, Marie-Philippe Saltiel, Pauline Reynier, Laurent Azoulay, Oriana H Y Yu, Kristian B Filion. Acta Diabetol 2018
58
22


Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
22

SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus.
Michael d'Emden, John Amerena, Gary Deed, Carol Pollock, Mark E Cooper. Diabetes Res Clin Pract 2018
13
22

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
William C Knowler, Elizabeth Barrett-Connor, Sarah E Fowler, Richard F Hamman, John M Lachin, Elizabeth A Walker, David M Nathan. N Engl J Med 2002
22

Pioglitazone and bladder cancer risk: a systematic review and meta-analysis.
Huilin Tang, Weilong Shi, Shuangshuang Fu, Tiansheng Wang, Suodi Zhai, Yiqing Song, Jiali Han. Cancer Med 2018
29
22

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
William C Knowler, Sarah E Fowler, Richard F Hamman, Costas A Christophi, Heather J Hoffman, Anne T Brenneman, Janet O Brown-Friday, Ronald Goldberg, Elizabeth Venditti, David M Nathan. Lancet 2009
22

An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus.
Daniel S Hsia, Owen Grove, William T Cefalu. Curr Opin Endocrinol Diabetes Obes 2017
61
22

Characterization of [¹²⁵I]GLP-1(9-36), a novel radiolabeled analog of the major metabolite of glucagon-like peptide 1 to a receptor distinct from GLP1-R and function of the peptide in murine aorta.
Rhoda E Kuc, Janet J Maguire, Keith Siew, Sheena Patel, David R Derksen, V Margaret Jackson, Kevin M O'Shaughnessey, Anthony P Davenport. Life Sci 2014
7
14



Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
326
11

Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.
F Xavier Pi-Sunyer, Anja Schweizer, David Mills, Sylvie Dejager. Diabetes Res Clin Pract 2007
214
11

Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus.
Michael J Barry, Linda L Humphrey, Amir Qaseem. Ann Intern Med 2017
2
50

Standards of medical care for type 2 diabetes in China 2019.
Weiping Jia, Jianping Weng, Dalong Zhu, Linong Ji, Juming Lu, Zhiguang Zhou, Dajin Zou, Lixin Guo, Qiuhe Ji, Li Chen,[...]. Diabetes Metab Res Rev 2019
76
11

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
A J Scheen. Diabetes Obes Metab 2010
176
11

The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus.
T Forst, B Uhlig-Laske, A Ring, A Ritzhaupt, U Graefe-Mody, K A Dugi. Diabetes Obes Metab 2011
43
11


Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.
Markolf Hanefeld, Gary A Herman, Mei Wu, Carolyn Mickel, Matilde Sanchez, Peter P Stein. Curr Med Res Opin 2007
118
11


[Disturbances of lipoprotein metabolism in metabolic syndrome].
Marta Czyzewska, Anna Wolska, Agnieszka Cwiklińska, Barbara Kortas-Stempak, Małgorzata Wróblewska. Postepy Hig Med Dosw (Online) 2010
5
20

GRADE guidelines: 3. Rating the quality of evidence.
Howard Balshem, Mark Helfand, Holger J Schünemann, Andrew D Oxman, Regina Kunz, Jan Brozek, Gunn E Vist, Yngve Falck-Ytter, Joerg Meerpohl, Susan Norris,[...]. J Clin Epidemiol 2011
11

Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
B Bode, K Stenlöf, S Harris, D Sullivan, A Fung, K Usiskin, G Meininger. Diabetes Obes Metab 2015
131
11

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.
Muhammad Abdul-Ghani, Stefano Del Prato, Robert Chilton, Ralph A DeFronzo. Diabetes Care 2016
169
11

The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
Aino Latva-Rasku, Miikka-Juhani Honka, Joel Kullberg, Nina Mononen, Terho Lehtimäki, Juha Saltevo, Anna K Kirjavainen, Virva Saunavaara, Patricia Iozzo, Lars Johansson,[...]. Diabetes Care 2019
40
11

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.
Larissa Shamseer, David Moher, Mike Clarke, Davina Ghersi, Alessandro Liberati, Mark Petticrew, Paul Shekelle, Lesley A Stewart. BMJ 2015
11


Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C Broedl, Hans J Woerle. Diabetes Care 2014
232
11

Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses.
Xin Sun, Matthias Briel, Stephen D Walter, Gordon H Guyatt. BMJ 2010
389
11

Pathophysiology of Diabetic Dyslipidemia.
Tsutomu Hirano. J Atheroscler Thromb 2018
61
11

The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses.
W G Melsen, M C J Bootsma, M M Rovers, M J M Bonten. Clin Microbiol Infect 2014
183
11

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Heidi Storgaard, Lise L Gluud, Cathy Bennett, Magnus F Grøndahl, Mikkel B Christensen, Filip K Knop, Tina Vilsbøll. PLoS One 2016
92
11

Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.
Toshiyuki Hayashi, Tomoyasu Fukui, Noriko Nakanishi, Saki Yamamoto, Masako Tomoyasu, Anna Osamura, Makoto Ohara, Takeshi Yamamoto, Yasuki Ito, Tsutomu Hirano. Cardiovasc Diabetol 2017
60
11

Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS).
Hirohito Sone, Sachiko Tanaka, Shiro Tanaka, Satoshi Iimuro, Koji Oida, Yoshimitsu Yamasaki, Shinichi Oikawa, Shun Ishibashi, Shigehiro Katayama, Yasuo Ohashi,[...]. J Clin Endocrinol Metab 2011
115
11


Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
573
11

Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
Lindsay E Clegg, Hiddo J L Heerspink, Robert C Penland, Weifeng Tang, David W Boulton, Srinivas Bachina, Robert D Fox, Peter Fenici, Marcus Thuresson, Robert J Mentz,[...]. Diabetes Care 2019
15
11

Recent progress of sodium-glucose transporter 2 inhibitors as potential antidiabetic agents.
Yajing Zhang, Huazhuo Ban, Runan Yu, Zhijian Wang, Dayong Zhang. Future Med Chem 2018
5
20


New insights into the pathophysiology of dyslipidemia in type 2 diabetes.
Marja-Riitta Taskinen, Jan Borén. Atherosclerosis 2015
175
11

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk.
Anastasia Erythropoulou-Kaltsidou, Georgios Polychronopoulos, Konstantinos Tziomalos. Diabetes Ther 2020
6
16


Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Chantal Mathieu, Aurelian Emil Ranetti, Danshi Li, Ella Ekholm, William Cook, Boaz Hirshberg, Hungta Chen, Lars Hansen, Nayyar Iqbal. Diabetes Care 2015
80
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.